Unknown

Dataset Information

0

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy.


ABSTRACT: We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (?CD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8(+) T cell responses and augment T cell anti-tumor effects. We devised a regimen in which anti-CTLA-4 was administered late so as to delay contraction and minimize toxicities. This late administration both enhanced and prolonged CD8 T cell activation without the need for additional IL-2. The quality of the T cell response was improved with increased frequency of effector/effector memory phenotype cells along with improved lytic ability and bystander expansion. This enhanced CD8 response translated to improved anti-tumor responses both at the primary and metastatic sites. Importantly, toxicities were not exacerbated with combination. This study provides a platform for rational design of immunotherapy combinations to maximize anti-tumor immunity while minimizing toxicities.

SUBMITTER: Sckisel GD 

PROVIDER: S-EPMC4782757 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy.

Sckisel Gail D GD   Mirsoian Annie A   Bouchlaka Myriam N MN   Tietze Julia K JK   Chen Mingyi M   Blazar Bruce R BR   Murphy William J WJ  

Cancer immunology, immunotherapy : CII 20150930 12


We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8(+) T cell responses and augment T cell anti-tu  ...[more]

Similar Datasets

| S-EPMC5821191 | biostudies-literature
| S-EPMC5939050 | biostudies-literature
| S-EPMC4721659 | biostudies-literature
| S-EPMC3666941 | biostudies-literature
| S-EPMC7068049 | biostudies-literature
| S-EPMC5601925 | biostudies-literature
| S-EPMC7372940 | biostudies-literature
| S-EPMC5551571 | biostudies-literature
| S-EPMC7851258 | biostudies-literature
| S-EPMC3654853 | biostudies-literature